FUNDAMENTALS |
MarketCap: |
3.65 mill
|
EPS: |
-0.200
|
P/E: |
-0.180
|
Earnings Date: |
Mar 28, 2024 |
SharesOutstanding: |
100.08 mill
|
Avg Daily Volume: |
0.117 mill
|
RATING
2024-03-28 |
C+
|
Sell
|
RATINGS |
Rating CashFlow: |
Strong Sell
|
|
Return On Equity: |
Strong Buy
|
|
Return On Asset: |
Sell
|
|
DE: |
Strong Sell
|
|
P/E: |
Sell
|
|
Price To Book: |
Strong Sell
|
|
QUARTER GROWTHS |
|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 |
Revenue | n/a | | | | n/a | n/a |
Gr.Profit | n/a | | | | n/a | n/a |
Ebit | | | | | | |
Asset | | | | | | |
Debt | | | | | | |
PE RATIO: COMPANY / SECTOR |
0.00x
|
Company: PE -0.180 | sector: PE 12.30
|
PE RATIO: COMPANY / INDUSTRY |
0x
|
Company: PE -0.180 | industry: PE -5.55
|
DISCOUNTED CASH FLOW VALUE |
$-0.0182
(-149.85%)
$-0.0547
|
Date: 2024-03-28
|
Expected Trading Range (DAY) |
$ 0.0275 - 0.0455
( +/- 24.66%)
|
ATR Model: 14 days
|
Insider Trading
Date |
Person |
Action |
Amount |
type |
2023-11-27 | Scott John K Jr. | Buy | 64 289 | Series J Convertible Preffered Stock |
2023-11-27 | Scott John K Jr. | Sell | 2 270 | Series G Redeemable Preferred Stock |
2023-11-27 | Scott John K Jr. | Sell | 2 400 | Series I Convertible Preferred Stock |
2023-11-16 | Moss Dana J | Buy | 416 667 | Common Stock |
2023-11-16 | Moss Dana J | Buy | 200 000 | Common Stock |
INSIDER POWER |
99.82
|
Last
95 transactions |
Buy:
26 134 406 | Sell:
71 109 |
Forecast:
16:00 - $0.0365
Live Trading Signals (every 1 min)
Forecast
1: 15:16 - $0.0380
Forecast 2: 16:00 - $0.0365
Forecast 3: 16:00 - $0.0365
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals |
RSI 21 |
|
SMA |
|
Trend |
|
Trend 2 |
|
Trend 3 |
|
MACD |
|
Volume Signals |
Price |
$0.0365 (2.82% )
|
Volume |
0.0642 mill
|
Avg. Vol. |
0.117 mill
|
% of Avg. Vol |
55.06 %
|
Signal 1: |
|
Signal 2: |
|
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For NAVB
0 Signals |
Accuracy: 0.00% | Accuracy
Buy: 0.00% | Accuracy
Sell: 0.00%
Avg return
buy: 0.00 % | Avg return
sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.